Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells much faster than with current methods by using a simpler process.

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), proudly announces the launch of its new mission statement and tagline: Empowering Partners. Enriching Lives. This ...

Shares in vaccine developer Vaxcyte soared by over 35% Tuesday after the company unveiled results from a large study testing its experimental pneumococcal shot that analysts described as a best-case ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

As a Sapio Services Partner, Astrix will provide services around the deployment and support of the Sapio Platform, Sapio LIMS, and Sapio ELN. Astrix works with clients to fundamentally improve ...

U.K.-based biotechnology company F2G has raised $100 million to complete late-stage testing of a new kind of antifungal treatment and bring it back to U.S. regulators’ desks after they rejected it ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

The funding will support mid-stage testing of a drug the company believes to have the potential to treat a range of neurodegenerative conditions.

Boston, MA – The much-anticipated RE•WORK AI in Healthcare & Pharma Summit is set to take place on November 13-14, 2024, at ...